 | Up a level |
Reubi, J.C.; Perren, A; Rehmann, R; Waser, B; Christ, E; Callery, M; Goldfine, A B; Patti, M E (2010). Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass. Diabetologia, 53(12), pp. 2641-5. Heidelberg: Springer-Verlag 10.1007/s00125-010-1901-y
de Visser, M; Bernard, H F; Erion, J L; Schmidt, M A; Srinivasan, A; Waser, B; Reubi, J. C.; Krenning, E P; de Jong, M (2007). Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. European journal of nuclear medicine and molecular imaging, 34(8), pp. 1228-38. Berlin: Springer 10.1007/s00259-006-0356-3
Antunes, P; Ginj, M; Zhang, H; Waser, B; Baum, R P; Reubi, J. C.; Maecke, H (2007). Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? European journal of nuclear medicine and molecular imaging, 34(7), pp. 982-93. Berlin: Springer 10.1007/s00259-006-0317-x
Storch, D; Schmitt, JS; Waldherr, C; Waser, B; Reubi, Jean-Claude; Maecke, HR (2007). Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals. Radiochimica acta, 95(6), pp. 359-69. München: Oldenbourg 10.1524/ract.2007.95.6.359
Chatenet, D; Cescato, R; Waser, B; Rivier, J; Reubi, JC (2011). Synthesis and characterization of DOTA-coupled dimeric Y1 receptors antagonists for breast cancer targeting. In: Lebl, M (ed.) Proceeding of the 22nd American Peptide Symposium. American Peptide Society
Rivier, J; Gulyas, J; Erchegyi, J; Koerber, SC; Grace, C; Riek, R; DiGruccio, M; Perrin, M; Rivier, C; Eltschinger, V; Waser, B; Cescato, R; Reubi, J.C.; Vale, W (2006). Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists. In: Insights into Receptor Function and New Drug Development Targets (pp. 117-138). Heidelberg: Springer Verlag 10.1007/3-540-34447-0_8
